Table 2 CCND1.COMT interaction in breast cancer cases from Ontario and Finland populations.
From: Combined effect of CCND1 and COMT polymorphisms and increased breast cancer risk
| Â | Â | ONTARIO | FINLAND | ||||||
|---|---|---|---|---|---|---|---|---|---|
Combined Enzymatic Activity | Combined Genotype | Controls N (%) | Cases N (%) | OR | CI | Controls N (%) | Cases N (%) | OR | CI |
CCND1Low/COMTLow | GGAA | 73 (10.2) | 74 (6.1) | 1.0 | - | 51 (9.4) | 52 (7.4) | 1.0 | - |
CCND1Low/COMTMedium, CCND1Low/COMTHigh, CCND1Medium/COMTMedium, CCND1Medium COMTLow, CCND1Medium COMTHigh, CCND1High/COMTLow | GGAG, GGGG, AGAG, AGAA, AGGG, AAAA | 534 (74.4) | 897 (73.6) | 1.66 | 1.18–2.33 | 416 (76.6) | 515 (73.4) | 1.21 | 0.81–1.83 |
CCND1High/COMTMedium, CCND1High/COMTHigh | AAAG, AAGG | 107 (14.9) | 240 (19.8) | 2.22 | 1.49–3.28 | 76 (14) | 134 (19.1) | 1.73 | 1.08–2.78 |
| Â | Total | 714 | 1211 | Â | Â | 543 | 701 | Â | Â |
Trend Test | p = 0.00013 | p = 0.012 | |||||||